Industry News
– Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg – – Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially…
Read More
First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway. Excerpt from the Press Release: WALTHAM, Mass. (January 10, 2023) – ScipherMedicine, a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data and analytics capabilities. The…
Read More
Excerpt from the Press Release: PRINCETON, N.J., January 18, 2023 – Taiho Oncology, Inc. today announced the publication of results from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in the January 19, 2023 issue of The New England Journal of Medicine (NEJM). The article, “Futibatinib for Intrahepatic Cholangiocarcinoma with FGFR2 Fusions/Rearrangements,” reports on…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initiated its “PHASE IIB/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF A SINGLE INTRAVENOUS INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS TO SUBJECTS WITH…
Read More
Excerpt from the Press Release: FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, presented the results of the…
Read More
Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / January 19, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers. Historically,…
Read More
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET Excerpt from the Press Release: BOSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the presentation of data from a Phase 2 study of…
Read More
IND demonstrates Mirati’s leadership in KRAS, representing the Company’s third KRAS or KRAS-signaling program to enter clinical development Excerpt from the Press Release: SAN DIEGO, Jan. 19, 2023 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of MRTX1133, a potential…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ — Vial, a global tech-enabled CRO providing next-generation clinical trial management services, announced that the first patient has been enrolled in the clinical trial TLL018-205, a Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of TLL-018 in human subjects with moderate…
Read More
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of six patients treated are still on study and PSA values are being followed up Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., Jan. 12, 2023…
Read More